Solutions for Detection of Apoptosis in Oncology Xenograft Models
At DiaPharma, we specialize in biomarker assays designed to advance oncology research. One of the hallmarks of cancer is the evasion of apoptosis by tumor cells—making the detection of cellular death, especially apoptosis, a critical readout in the evaluation of anti-cancer therapies.
Xenograft models are widely used in oncology research to study cancer therapies in vivo. However, methods for evaluating the effect of potential drug candidates on tumor growth—such as volume measurements, imaging, or immunohistochemical staining—are often imprecise, expensive, technically demanding, or require sacrificing the xenograft host.
This blood-based biomarker assay utilizes the M30® antibody which specifically detects a caspase-cleaved fragment of cytokeratin 18 (CK18), a cytoskeletal protein expressed in epithelial cells and cleaved by caspases early during apoptosis. The cleaved CK18 fragment (ccK18) is released into the bloodstream, and its concentration in serum or plasma measured with the M30 Apoptosense® ELISA correlates with the extent of epithelial cell apoptosis.
Why choose the M30 Apoptosense® ELISA for use with your xenograft model?
● The M30® antibody is highly specific for human ccK18 and does not cross-react with murine proteins, enabling precise detection of apoptosis of human tumor cells with xenograft models.
● Minimally invasive blood sampling allows for longitudinal assessment of treatment response.
● The assay provides sensitive, quantitative measurements to evaluate dose- and time-dependent effects of potential drug candidates.
● Incorporating the M30® biomarker offers a robust, translational tool to strengthen efficacy assessments — particularly valuable for bridging preclinical findings to clinical applications.
We would be happy to provide more detailed information tailored to your research. Please don’t hesitate to reach out to our Scientists or your local DiaPharma Territory Manager.
*For research use only in US and Canada. Not for use in diagnostic procedures.
THE NEW NOVEL ANTICOAGULANTS XI(a) and XII(a). THE CONTACT FACTOR INHIBITORS: Battling thromboembolism. David L. McGlasson, MS, MLS(ASCP) INTRODUCTION Thromboembolism is a leading cause of mortality and morbidity. Treatment with anticoagulants is prescribed, but balancing bleeding and clotting has been a challenge. In the 1940s, unfractionated heparin (UFH) became available for use by intravenous or…
Non-Invasive Biomarker Assays for Liver Disease Drug Development Studies The Need: Non-Invasive, mechanistic biomarkers that add valuable information about your drug candidate’s efficacy Not all biomarkers provide information about the biological mechanism of drug candidates. Specific and comprehensive data are critical when deciding on a clinical trial strategy for a drug candidate. M30®-Apoptosense, M65®…
When it comes to measuring pancreatic Beta cell function, go with the Pro! TECO® Proinsulin ELISA Why Measure Intact Proinsulin? Proinsulin is the precursor of insulin and Connecting Peptide (C-Peptide). Following synthesis, proinsulin is packaged into secretory granules, where it is processed to C-Peptide and insulin by prohormone convertases (PC1/3 and PC2) and carboxypeptidase…
It’s Not Just Support. It’s Solutions. Markers for Bleeding and Thrombosis in Liver Disease DiaPharma’s long-time expertise in the Hemostasis and Liver Disease fields means we’re uniquely positioned to deliver solutions. Liver diseases – such as Non-alcoholic fatty liver disease (NAFLD), Alcoholic Hepatitis (AH), and cirrhosis – can be associated with imbalances in coagulation, whether…
It’s Not Just Support. It’s Solutions. Staff Spotlight Meet Nancy, Executive Assistant We’re excited to welcome Nancy to the DiaPharma team. Nancy writes, “I was born in Farmington Hills Michigan. I have three children; my youngest daughter Brenna is still at home while attending University of Cincinnati. I have been with my husband Tim for…
It’s Not Just Support. It’s Solutions. Chromogenic Substrates for your Coagulation, Anticoagulation, and Fibrinolysis Needs Chromogenic substrate technology is in our blood. Chromogenic Substrates for QC, Drug Development, R&D, for Anti-Xa Testing (S-2765), Contact Pathway Studies (S-2302), Thrombin Generation (S-2238), and more. Chromogenic substrates are peptides that react with proteolytic enzymes with the formation of…
A Trio of Biomarkers: A Novel Multivariate Model to Detect DILI & Liver Damage -Contributed by Abi Kasberg, PhD While maybe underappreciated, Drug-induced liver injury (DILI) is a condition with significant impact on the medical world. DILI is the leading cause of acute liver failure and is frequently responsible for the termination and withdrawal of…
Clot Club – ISTH 2021 David L. McGlasson, MS, MLS(ASCP) Attending the International Society of Thrombosis and Hemostasis 2021 virtually from July 17-21, 2021 was quite a challenge this year. There were lots of information ranging from clinical, to what I would call “futuristic” research, that we might not see put into clinical practice for…
It’s Not Just Support. It’s Solutions. Biomarker Assays for NASH Clinical Trials Non-Invasive Biomarkers for Fatty Liver Disease Research The Problem: In early phase NASH trials, performing liver biopsies to evaluate the effect of a potential drug candidate is not always practical or feasible. These relatively short-duration early trials may not result in significant changes…
It’s Not Just Support. It’s Solutions. September is National Sickle Cell Awareness Month, a time to acknowledge and educate how this often-invisible and rare disease impacts over 100,000 people in the U.S., most of whom are of African descent. Treatment can include antibiotics, pain management, intravenous fluids, blood transfusion and surgery. Sickle Cell Disease Association…
Thrombotic Thrombocytopenic Purpura (TTP) Clinical Trials: Targeting the needs left by current treatment options -Contributed by Abi Kasberg, PhD Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy blood disorder that is characterized by the formation of blood clots in small blood vessels, thrombocytopenia, and a lack of ADAMTS-13 (a disintegrin-like and metalloproteinase with thrombospondin…
It’s Not Just Support. It’s Solutions. Save Time with CMV Brite™ Turbo Early and rapid diagnosis of active CMV infection is of great importance in avoiding overtreatment with immunosuppressive drugs and in guiding antiviral therapy. The CMV Brite™ Turbo Kit is a rapid immunofluorescence antigenemia kit for in vitro CMV diagnosis. The CMV Brite™ Turbo…
It’s Not Just Support. It’s Solutions. Anti-Hemoglobin S antibodies from DiaPharma Introducing a new monoclonal antibody for detection of HbS in flow cytometry applications. Now, researchers can accurately measure HbS distribution within a sample, giving additional information on distribution of hemoglobins. This unique antibody offering can be used in conjunction with additional flow cytometry antibodies…
It’s Not Just Support. It’s Solutions. Ceveron® s100: Your all-in-one coagulation research analyzer Featuring automated ADAMTS13, Thrombin Generation Testing, FXIII, and full menu of clotting and chromogenic tests Scientists will be excited to learn about the do-it-all Ceveron® s100, for automated hemostasis research assays. You name it, Ceveron® s100 can do it! Featuring Technofluor® ADAMTS13…
Platelet Party? Let T-TAS® 01 be your designated driver. Use the leading edge in impaired primary hemostasis assessment and get results quickly with whole blood. The DiaPharma Group is excited to provide Fujimori Kogyo/Zacros’s T-TAS® 01 system – an automated microchip flow chamber system developed for the quantitative assessment of the thrombus formation process under…
In vitro Liver Culture Systems to Investigate DILI Contributed by Abi Kasberg, PhD An important function of the liver is to concentrate and metabolize drugs and xenobiotics, which makes the liver vulnerable to tissue damage. Drug-induced Liver Injury (DILI) is the onset of liver damage caused by drugs, medications, or supplements. DILI is associated with…
It’s Not Just Support. It’s Solutions. Save with every screening. By screening for Factor V Leiden with the Coatest® APC™ Resistance V kit from DiaPharma, your lab could save thousands of dollars. Each kit was designed to be easy to use for in-house screening, offering fast results and low costs for both large and small…
It’s Not Just Support. It’s Solutions. Full portfolio of von Willebrand Disease Research Products vWF Activity, Antigen, Collagen Binding, Propeptide, and more. From DiaPharma. Product Spotlight: vWFpp Senova vWF propeptide ELISA* New! Convenient ELISA for research related to vWF clearance mechanisms Rapid double monoclonal ELISA: < 90 min assay time Pre-coated strips make the assay…
It’s Not Just Support. It’s Solutions. DiaPharma is Your Exclusive Source For ProAxsis ProteaseTag™ Active Neutrophil Elastase Assay The Problem Assessing active protease levels in complex biological samples such as sputum or bronchoalveolar lavage samples are problematic due to a lack of reliable and robust methodologies, which result in data with high variability and limited…
It’s Not Just Support. It’s Solutions. Meet the Team We welcomed several new members, 2-legged and 4-legged, to the DiaPharma family during the pandemic! Mary Alice Our Senior Support Scientist, Abi, welcomed daughter Mary Alice into their family last spring, shortly after the start of the pandemic! Mary Alice joins Abi, her husband, their three…
